Rome Therapeutics was founded to develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome.
The repeatome makes up 60% of our genome and consists of repetitive sequences of nucleic acids, known as repeats. These repeats have long been dismissed as “junk DNA.” Much of this region is thought to derive from viruses that embedded in our DNA millions of years ago. In healthy cells, DNA of the repeatome is tightly packed and silent. But when cells are stressed or sick, during circumstances like an infection, cancer or autoimmune disease, this repetitive DNA can unfold, causing the cell to transcribe it into RNA.
Rome believes that medicines targeting the repeatome could revolutionize the way many diseases are treated. The company has already picked out several targets to pursue in cancer and autoimmune disease and is working towards generating small molecule modulators of these targets. Multiple other discovery programs are underway.
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
